Pancreatic Cancer Research

Clinical trialPhase 1Active not recruiting

Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors

A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Advanced or Metastatic Solid Tumors

Outcome
Ongoing
Phase
Phase 1
Status
Active not recruiting
Study type
Interventional
Start
30 July 2025
Expected end
31 May 2027
Enrollment
160 participants
Sites
11
Primary outcomes
Participants with Dose-limiting toxicities; Participants with Serious Adverse Events (SAEs) and treatment-emergent adverse events (TEAEs); Participants with abnormal physical examination findings; Participants with ability to care for themselves, daily activity, and physical activity; Participants with abnormal ECG and ECHO/MUGA reading
Sponsor type
Industry
Results posted
No
Last update
5 August 2026

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

The objective of this study is to evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects with Advanced or Metastatic Solid Tumors.

Detailed description public domain (ClinicalTrials.gov)

This is a multicenter Phase 1, open-label study to evaluate the safety, tolerability, pharmacokinetic profile, and initial efficacy of BL-M05D1 in subjects with unresectable locally advanced or metastatic solid tumors that are known to potentially express CLDN18.2, including but not limited to gastric and gastroesophageal junction adenocarcinoma (G/GEJ AC), esophageal AC (EAC), pancreatic ductal AC (PDAC), and biliary tract cancer (BTC). Participants must have recurred or progressed on at least 1 line of prior systemic therapy (including adjuvant/neoadjuvant), have no other standard of care options, and have no available curative options. This study will be conducted in three parts (dose escalation, dose finding and dose expansion). Subjects will be dosed on Day 1 of a continuous 21-day treatment cycle.